Financials
Financial year 2025
MGS Pharma from Stavelot, company number BE1014761540, closed financial year 2025 with a result of € 54,885 after tax. For that financial year MGS Pharma recorded a gross margin of € 69,967 and equity of € 54,552. The company is profitable. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on April 24, 2026.
€ 54,552
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 54,885
Profit after tax over the fiscal year.
€ 63,690
Cash and bank balances on the last day of the fiscal year.
€ 833 paid out
2 % of the profit went to the shareholders, the rest stayed in the company.
People and assets in 2025
≈ 1
No payroll staff. One director, so that person most likely runs the business.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 790
Supplier invoices still open on the last day of the fiscal year.
€ 12,027
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
What happened to MGS Pharma?
What happened at MGS Pharma in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 54,885. Source: NBB ↗
- New establishment in Stavelot. KBO
- Louise MAGIS became a director. NBB
- Start of the company according to the CBE. KBO
In short
Paid € 14,994 in corporate taxes since 2025.
Paid out € 833 in dividends to the owners in total.
A new publication or filing at MGS Pharma? We notify you, reason included.
Follow MGS PharmaDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Directors
According to the 2025 annual accounts
Louise MAGIS
Director
since 2024
Establishments
Establishment units
Physical locations of this company
Rue des Longues Pièces 17
4970 Stavelot
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 1014.761.540
- VAT number
- BE 1014.761.540
- Registered office
- Rue des Longues Pièces 17, 4970 Stavelot
- Names & denominations
- MGS Pharma
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 7 October 2024
- Peppol
- Active · Active since 18 Nov 2025
- Activities · NACE
Detailhandel in farmaceutische producten
Overige zakelijke dienstverlening, neg